Semnur Eyes Potential $2.5B Acquisition of SP-102 as Business Combination With Denali Nears
Semnur Eyes Potential $2.5B Acquisition of SP-102 as Business Combination With Denali Nears
- Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))))).
- Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.
- Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))))) announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with the Securities and Exchange Commission (the "SEC") before the end of October 2024 for the previously announced proposed Business Combination with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))))), which provides for a pre-transaction equity value of Semnur of $2.5 billion.
- The closing of the Business Combination is expected to occur by the end of fourth quarter of 2024 or the first quarter of 2025.
- As previously disclosed, the Board of Directors of Scilex approved a resolution to authorize a potential dividend of up to 10% of Scilex's ownership interest in Semnur to Scilex shareholders, subject to registration statement of Semnur on file with the SEC. These shares will be freely tradable upon exchanging to Denali common shares after Business Combination.
- Scilex will set a record date for the dividend shares after Semnur registration statement on file with SEC.
- Semnur目前正在討論關於戰略區域和/或全球合作以及對SP-102的潛在直接收購。任何此類交易可能有望在與Denali Capital Acquisition Corp.（納斯達克：DECA，SPAC）合併之後提供超過25億美元的價值（「業務組合」）
- 根據Syneos Health Consulting（「Syneos」）進行的獨立市場調研，SP-102（SEMDEXA）的使用意圖強烈，預計在SP-102推出後的第5年達到每年360億美元的銷售潛力。
- Semnur Pharmaceuticals, Inc.（「Semnur」）是Scilex Holding Company（納斯達克：SCLX，「Scilex」）的全資子公司，宣佈預計將於2024年10月底之前向美國證券交易委員會（「SEC」）提交S-4表格（「註冊聲明」），用於先前宣佈的與Denali Capital Acquisition Corp.（納斯達克：DECA，「SPAC」）的擬議業務組合，該組合爲Semnur的價值設定了250億美元的交易前股權價值。
- 預計業務組合將在2024年第四季度或2025年第一季度結束。
- 正如先前披露的，Scilex的董事會批准了一項決議，授權將Scilex對Semnur的最高10％所有權利潤作爲潛在股息授權給Scilex股東，前提是Semnur的註冊聲明已在SEC備案。這些股票在業務組合後換股爲Denali普通股後將可以自由交易。
- Scilex將在Semnur與SEC備案後設定股息股份的登記日期。
PALO ALTO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it anticipates the filing of the Registration Statement with the SEC before the end of October 2024 relating to the previously announced proposed Business Combination with Denali Capital Acquisition Corp. (NASDAQ:DECA) for a pre-transaction equity value of $2.5 billion which transaction is expected to occur by the end of fourth quarter of 2024 or the first quarter of 2025.
加利福尼亞州帕洛阿爾託，2024年10月16日（環球新swire）-- Scilex Holding Company（納斯達克：SCLX，「Scilex」或「公司」），一家專注於收購、開發和商業化非阿片類疼痛管理產品以治療急性和慢性疼痛的創新產生收入的公司，今天宣佈，預計在2024年10月底之前向SEC提交與先前宣佈的與Denali Capital Acquisition Corp.（納斯達克：DECA）的擬議業務組合相關的註冊聲明，以250億美元的交易前股權價值，該交易預計將在2024年第四季度或2025年第一季度結束。
譯文內容由第三人軟體翻譯。
